Overview
ASND market data
Price History
ASND price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ASND. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275Benzinga · Jul 23, 2026, 6:05 PM
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280Benzinga · Jul 7, 2026, 4:05 PM
Ascendis Pharma Announces It Has Been Added To Multiple Russell U.S. Indexes, Including the Russell 3000, Russell 1000, Russell 2500 And Russell MidcapBenzinga · Jun 26, 2026, 8:10 PM
Watching Ascendis Pharma; Shares Spike Higher, Traders Circulate Unconfirmed M&A Blog Comments Suggesting Co In Final Talks To Be AcquiredBenzinga · Jun 25, 2026, 3:00 PM
Why Is Ascendis Pharma Stock Gaining Friday?Benzinga · Jun 12, 2026, 5:15 PM
Ascendis Pharma A/S Data From Phase 2 PaTH Forward Study Of TransCon PTH Demonstrates Sustained Efficacy, Safety In Participants With HypoparathyroidismBenzinga · Jun 11, 2026, 8:02 PM
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026Globenewswire Inc · Jun 8, 2026, 9:15 PM
Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $355Benzinga · May 19, 2026, 2:35 PM
Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $329Benzinga · May 15, 2026, 5:26 PM
Barclays Maintains Overweight on Ascendis Pharma, Raises Price Target to $345Benzinga · May 11, 2026, 1:14 PM